The in vivo dosing schedule is shown in Figure 6A. B16-F10 melanoma cells were inoculated on day 0, followed by intratumoral administration of PD-1-0520 from day 8 to day 21, and tumor tissues were collected on day 22 for subsequent analyses. Here, PDCD1 is linked to neoplasm.